1. Ip, C. (1981). Factors influencing the anticarcinogenic efficacy of selenium on dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats. Cancer Res.41, 2683–2686.
2.
2. Medina, D., Lane, H.W., and Tracy, C.M. (1983). Selenium and mouse tumorigenesis: An investigation of possible mechanisms. Cancer Res.43, 2460–2464.
3.
3. Thompson, H.J., Meeker, L.D., and Kokoska, S. (1984). Effect of an inorganic and organic form of dietary selenium on the promotional stage of mammary carcinogenesis in the rat. Cancer Res.44, 2803–2806.
4.
4. Woolley, P.V., and Schein, P.S. (1979). Clinical pharmacology and Phase I trial design. In: Methods in Cancer Research. New York: Academic Press, Vol. 17, pp. 177–198.
5.
5. Fox, S.M.R., Jacobs, R.M., Jones, A.O., Fry, B.E., Rakowska, M., Hamilton, R.P., Harland, B.F., Stone, C.L., and Tao, S.H. (1981). Animal models for assessing bioavailability of essential and toxic elements. Cereal Chem.58, 6–11.
6.
6. Thomson, C.D., Robinson, M.F., Campbell, D.R., and Rea, H.M. (1982). Effect of prolonged supplementation of selenomethionine and sodium selenite on glutathione peroxidase activity in blood of New Zealand residents. Am. J. Clin. Nutr.36, 24–31.
7.
7. Ray, J.H., and Altenburg, L.C. (1982). Sister-chromatid exchange induction by sodium selenite. Plasma protein-bound selenium is not the active SCE-inducing metabolite of Na2SO3. Mutation Res.102, 285–296.
